open access
Vol 58, No 2 (2024)
Invited Editorial
Submitted: 2023-12-27
Accepted: 2024-02-12
Published online: 2024-03-11
Get Citation
Significance of dysautonomia in Parkinson’s Disease and atypical parkinsonisms
1
, 1
, 1
Affiliations- Department of Neurology, Medical University of Warsaw, Warsaw, Poland
open access
Vol 58, No 2 (2024)
Invited editorials
Submitted: 2023-12-27
Accepted: 2024-02-12
Published online: 2024-03-11
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Significance of dysautonomia in Parkinson’s Disease and atypical parkinsonisms
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Invited Editorial
Pages
147-149
Published online
2024-03-11
Page views
160
Article views/downloads
129
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2024;58(2):147-149.
Authors
Piotr Alster
Natalia Madetko-Alster
References (30)- Hirsch L, Jette N, Frolkis A, et al. The incidence of parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology. 2016; 46(4): 292–300.
- Barer Y, Chodick G, Cohen R, et al. Epidemiology of progressive supranuclear palsy: real world data from the second largest health plan in israel. Brain Sci. 2022; 12(9).
- Constantinides VC, Paraskevas GP, Paraskevas PG, et al. Corticobasal degeneration and corticobasal syndrome: a review. Clin Park Relat Disord. 2019; 1: 66–71.
- Jellinger KA. Multiple system atrophy: a clinicopathological update. Free Neuropathol. 2020; 1.
- Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014; 44(4): 673–683.
- Jordan J, Shibao C, Biaggioni I. Multiple system atrophy: using clinical pharmacology to reveal pathophysiology. Clin Auton Res. 2015; 25(1): 53–59.
- Schmidt C, Herting B, Prieur S, et al. Autonomic dysfunction in patients with progressive supranuclear palsy. Movement Disorders. 2008; 23(14): 2083–2089.
- Altmann CF, Koschel J, Jost WH. Predictors of falls in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy: a retrospective study. Neurol Neurochir Pol. 2023; 57(3): 297–304.
- Koga S, Aiba I. Autonomic Dysfunction in Tauopathies. Brain Nerve. 2022; 74(3): 257–262.
- Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord. 2022; 37(6): 1131–1148.
- Kwaśniak-Butowska M, Dulski J, Pierzchlińska A, et al. Cardiovascular dysautonomia and cognition in Parkinson's Disease: a possible relationship. Neurol Neurochir Pol. 2021; 55(6): 525–535.
- Höglinger GU, Respondek G, Stamelou M, et al. Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017; 32(6): 853–864.
- Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80(5): 496–503.
- Kanazawa M, Tada M, Onodera O, et al. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. Parkinsonism Relat Disord. 2013; 19(12): 1149–1151.
- Yamawaki T. Diagnosis of MSA-P and PSP-P in Early Stage. Brain Nerve. 2020; 72(4): 331–343.
- Alster P, Nieciecki M, Migda B, et al. The strengths and obstacles in the differential diagnosis of Progressive Supranuclear Palsy-Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT). Diagnostics (Basel). 2022; 12(2).
- Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord. 2010; 25(3): 357–362.
- Malkiewicz JJ, Siuda J. Comparison of autonomic dysfunction in patients with Parkinson's Disease, progressive supranuclear palsy, and multiple system atrophy. Neurol Neurochir Pol. 2023 [Epub ahead of print].
- Madetko-Alster N, Otto-Ślusarczyk D, Wiercińska-Drapało A, et al. Clinical phenotypes of progressive supranuclear palsy-the differences in interleukin patterns. Int J Mol Sci. 2023; 24(20).
- Holmberg B, Kallio M, Johnels B, et al. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. Mov Disord. 2001; 16(2): 217–225.
- Kimber J, Mathias CJ, Lees AJ, et al. Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain. 2000; 123 ( Pt 7): 1422–1430.
- Holmberg B, Kallio M, Johnels B, et al. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. Mov Disord. 2001; 16(2): 217–225.
- Oliveira MCB, Ling H, Lees AJ, et al. Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2019; 90(5): 555–561.
- Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1999; 67(5): 620–623.
- Nojszewska M, Potulska-Chromik A, Jamrozik Z, et al. Electrophysiological and clinical assessment of dysautonomia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP): a comparative study. Neurol Neurochir Pol. 2019; 53(1): 26–33.
- Pilotto A, Romagnolo A, Scalvini A, et al. Association of orthostatic hypotension with cerebral atrophy in patients with lewy body disorders. Neurology. 2021; 97(8): e814–e824.
- Dayan E, Sklerov M, Browner N. Disrupted hypothalamic functional connectivity in patients with PD and autonomic dysfunction. Neurology. 2018; 90(23): e2051–e2058.
- Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014; 64(6): 1235–1240.
- Przewodowska D, Marzec W, Madetko N. Novel therapies for parkinsonian syndromes-recent progress and future perspectives. Front Mol Neurosci. 2021; 14.
- Sławek J, Jost WH. Botulinum neurotoxin in neurological practice: a leading topic in neurology. Neurol Neurochir Pol. 2021; 55(2): 120–124.
